http://www.ophthotech.com Mon, 26 Apr 2010 11:35:21 +0000 http://backend.userland.com/rss092 en Anti-PDGF Aptamer E10030 to be Dosed in Combination with Lucentis® Princeton, NJ – April 26, 2010 – Ophthotech Corp. (“Ophthotech”), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of ... http://www.ophthotech.com/first-patient-phase-ii-10030/ --Company Plans to Initiate Phase 2 Combination Study with E10030 in Wet Age-related Macular Degeneration, Advance Two Additional Clinical State Programs in Macular Degeneration-- NEW YORK, December 15, 2009 -- Ophthotech Corp., a biopharmaceutical company focused on developing novel ophthalmic therapies for both wet and dry age-related macular degeneration (AMD), announced ... http://www.ophthotech.com/series-b-financing/ Press Release - April 26, 2010: Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration   http://www.ophthotech.com/press-release-apr-26-2010/ 59% of patients showed 3-line gain (significant visual gain) and 100% neovascular regression Fort Lauderdale, Fla, May 4, 2009 – Ophthotech Corp. today announced positive results of a phase 1 clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to ... http://www.ophthotech.com/positive-results/ Ophthotech Corp. 5 Vaughn Drive Suite 106 Princeton, NJ 08540 Phone (609) 945-6050 Fax (609) 452-7435 Map & Directions   Ophthotech Corp. One Penn Plaza 35th Floor New York, NY 10119 Phone (212) 845-8200 Fax (212) 845-8250 Map & Directions http://www.ophthotech.com/316/ SV Life Sciences was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. The company's first fund closed in 1994 raising $100m. SV Life Sciences now has four funds with current committed capital of more than $900m. Its team of 29 professionals ... http://www.ophthotech.com/sv-life-sciences/ Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds that have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and key decision makers allow ... http://www.ophthotech.com/clarus-ventures/ HBM Partners AG, founded in 2001, is one of the world’s leading investment advisory groups in the sectors of biotechnology, emerging pharma and medical technology. The group invests globally in private, as well as public companies. The HBM team of professionals has extensive experience in drug and medical device ... http://www.ophthotech.com/hbm-partners/ Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. The Novo Ventures team consists of six Partners in Copenhagen, ... http://www.ophthotech.com/novo-as/ Princeton, NJ and New York, NY- November 10, 2008 - Ophthotech Corp., announced today the treatment of its first patient with Volociximab, a monoclonal antibody targeting α5β1 integrin, in a Phase I trial for the treatment of wet age-related macular degeneration (AMD). Ophthotech is a privately held biopharmaceutical company focused ... http://www.ophthotech.com/ophthotech-treats-first-patient-in-a-phase-i-trial-of-monoclonal-antibody-volociximab-for-age-related-macular-degeneration/